Related Experiment Video
Updated: Jul 2, 2025
04:44
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
19.9K
Nintedanib in systemic sclerosis treatment: a case report
Maysoun Kudsi1, Raghad Tarcha2, Naram Khalayli3
1Department of Rheumatology, Faculty of Medicine, Damascus University, Al-Mazzeh, Damascus, Syria.
Journal of Medical Case Reports
|February 22, 2024
Summary
Nintedanib effectively slows lung function decline in systemic sclerosis patients. This treatment showed safety and improved kidney function and pulmonary tests in a case study, offering hope for systemic sclerosis management.
Area of Science:
- Rheumatology
- Pulmonology
- Pharmacology
Background:
- Systemic sclerosis is a complex autoimmune disease affecting multiple organs.
- Interstitial lung disease (ILD) and scleroderma renal crisis (SRC) are severe complications.
- Nintedanib is an approved treatment for systemic sclerosis-associated ILD, aiming to reduce forced expiratory volume decline.
Observation:
- A 48-year-old female with diffuse systemic scleroderma presented with acute breathlessness, nausea, palpitations, and severe headache.
- The patient had a history of pulmonary hypertension, ILD, and SRC, with a modified Rodnan score of 18.
- Treatment initiated included captopril and oral nintedanib (150 mg/day).
Findings:
- After 12 months, the patient exhibited normal kidney function and improved pulmonary function tests.
- The modified Rodnan score decreased from 18 to 10, indicating reduced skin thickening.
- No adverse side effects related to nintedanib were observed in this case.
Implications:
- Nintedanib demonstrates potential in slowing lung function decline in systemic sclerosis.
- The case suggests nintedanib may be safe and effective in managing systemic sclerosis complications, including renal and pulmonary involvement.
- Further research is warranted to explore nintedanib's role in advancing systemic sclerosis treatment paradigms.
